Natco Pharma Limited
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas.NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.
What Natco files
- Others62
- Investor Meet41
- Updates27
- Dividend/Bonus10
- Board Meeting9
- PPTs7
Natco Pharma invested an additional US$ 14 million in eGenesis, Inc., bringing its total investment to US$ 22 million. eGenesis pioneers genome engineering for transplantable organs, addressing global organ shortages.
NATCO Pharma's Visakhapatnam FDF unit completed a US FDA inspection, receiving a Form 483 with 4 observations. The company believes these are procedural and is confident in addressing them, indicating minimal impact.
NATCO Pharma received tentative US FDA approval for Olaparib tablets. Alembic Pharma will distribute this drug, which had estimated US sales of ~$1.4 billion. Para IV litigation is ongoing.
NATCO Pharma completed acquiring an additional 13.25% stake in Adcock Ingram for ₹1,060 Cr. This increases NATCO's shareholding to 49%, marking a strategic milestone in its African growth journey.
NATCO Pharma and Lupin secured U.S. FDA approval for Eribulin Mesylate Injection, a generic equivalent to Halaven®. This drug targets metastatic breast cancer and liposarcoma, tapping into a U.S. market with estimated annual sales of ~$363 Cr.